Format

Send to

Choose Destination
See comment in PubMed Commons below
Ann Pharmacother. 2011 Mar;45(3):335-41. doi: 10.1345/aph.1P719. Epub 2011 Mar 8.

New measure of adherence adjusted for prescription patterns: the case of adults with asthma treated with inhaled corticosteroid monotherapy.

Author information

1
Faculté of Pharmacy, Université de Montréal, and Research Center, Hôpital du Sacré-Coeur de Montréal, Montréal, Québec, Canada. lucie.blais@umontreal.ca

Abstract

BACKGROUND:

Common measures of adherence to prescribed medications derived from administrative databases reflect both patients' and physicians' behavior, even if the measures are often interpreted as reflecting only the patient's adherence. Adherence to inhaled corticosteroids (ICSs) has been shown to be low among patients with asthma.

OBJECTIVE:

To develop a new measure of patients' adherence adjusted for prescription patterns and to evaluate the extent to which the low use of ICSs in asthma is due to patients' nonadherence or suboptimal prescribing practices.

METHODS:

The new measure of adherence, called the proportion of prescribed days covered (PPDC), is defined as the ratio of the total days' supply dispensed to the total days' supply prescribed during the study period. The PPDC is a modification of an existing adherence measure, the proportion of days covered (PDC). The PPDC and PDC for ICSs, therapy that should be prescribed for chronic daily use to patients with persistent asthma, were compared within a cohort of 4190 ICS-naïve patients with asthma aged 18-45 years derived from the administrative health databases of Quebec, Canada. We estimated the mean and the 95% confidence interval of the PPDC and PDC for ICSs over 1 year, and we calculated the part of nonadherence attributed to patients when measured with the PDC that can be attributed to nonoptimal prescribing of ICSs for chronic daily use with the following formula: [(1-PDC)-(1-PPDC)]/(1-PDC).

RESULTS:

The mean PPDC and PDC during the 1-year study were 52.6% (95% CI 51.6 to 53.6) and 19.1% (95% CI 18.6 to 19.6), respectively. Forty-one percent of nonadherence attributed to patients when measured with the PDC could be, in fact, attributed to nonprescribing of ICSs for chronic daily use.

CONCLUSIONS:

Our new adherence measure, the PPDC, may be considered as another way to assess patient adherence, taking into account differing prescribing patterns.

PMID:
21386018
DOI:
10.1345/aph.1P719
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center